Updated
Updated · guardonline.com · Jun 19
MMJ International Advances D.C. Circuit Challenge to April 22 Marijuana Schedule III Order
Updated
Updated · guardonline.com · Jun 19

MMJ International Advances D.C. Circuit Challenge to April 22 Marijuana Schedule III Order

3 articles · Updated · guardonline.com · Jun 19

Summary

  • June 18 filings put MMJ International’s challenge to the federal marijuana rescheduling order squarely before the D.C. Circuit, alongside its May 29 petition for review and June 9 joint stay motion.
  • MMJ argues the April 22 Schedule III order was issued before the hearing process required by the Controlled Substances Act, after the government ended a hearing track that had been underway since 2024.
  • The companies also contend the order exceeds statutory authority, violates the Administrative Procedure Act, conflicts with treaty obligations and D.C. Circuit precedent, and harms federally compliant cannabinoid-drug developers.
  • MMJ says DEA’s own 2020 rule drew a line between state-licensed marijuana products and federally regulated medicines, underscoring its claim that rescheduling cannot bypass FDA, DEA registration and manufacturing standards.
  • The case now shifts attention from a June 29 hearing to appellate review that could determine whether the Schedule III order stands or is vacated.

Insights

As legal battles split cannabis regulation, will a two-tiered market help or hinder medical progress?
With cannabis now both a Schedule I and Schedule III drug, who are the real winners and losers?
Can science overcome the challenge of turning an inconsistent plant into a predictable, FDA-approved medicine?